ClinicalTrials.gg
TerminatedNCT05271370Updated Oct 30, 2025Results posted

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

A Phase 2/3 interventional study of PRO 140 350 and PRO 140 525 in HIV-1-infection, sponsored by CytoDyn, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Aug 2017, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC (subcutaneous) monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects.

Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one-week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.

Read the detailed description

The objective is to assess the long-term safety of using PRO 140 350mg, 525mg, or 700mg SC as single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have completed 48 weeks of treatment in PRO140_CD03 study.
  2. Last known Plasma -1 RNA \< 50 copies/mL within PRO140_CD03 study.
  3. Both male and female patients and their partners of must agree to use 2 medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
  4. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written .

Exclusion criteria

Exclusion Criteria:

  1. Not currently enrolled in PRO140_CD03 study.
  2. Any active infection or requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma).
  3. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.
  4. Subjects weighing \< 35kg.
  5. History of anaphylaxis to any oral or parenteral drugs.
  6. History of Bleeding Disorder or patients on anti-coagulant therapy (except aspirin).

    Note: Subjects with well-controlled bleeding disorder while on stable anti-coagulant therapy dose with documented stable INRs can be enrolled as per discretion of the Investigator.

  7. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    PRO 140 350 mg

    PRO 140 350mg weekly SC injection.

    Drug: PRO 140 350

  • Experimental
    PRO 140 525 mg

    PRO 140 525mg weekly SC injection.

    Drug: PRO 140 525

  • Experimental
    PRO 140 700 mg

    PRO 140 700mg weekly SC injection.

    Drug: PRO 140 700

Interventions

06

What researchers measure

Primary outcomes

  1. Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.

    The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table). Treatment-Emergent Serious Adverse Events (TESAEs) are defined as serious adverse events with an onset on or after the first treatment.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

  2. Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.

    Virological failure is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

Secondary outcomes

  1. Time to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group.

    Virological failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group. The date of VF event is defined as the date of the second assessment of the two (2) consecutive HIV-1 RNA levels of \>= 200 copies/mL when virological failure is confirmed. Subjects who did not have VF, the last visit date will be used as the date of the event.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

  2. Proportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.

    Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

  3. Time to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.

    Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

  4. Proportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group.

    Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group. Subjects who experienced virologic failure during the treatment phase had an option to re-initiate their PRO 140 regimen to their previous baseline or dose escalate to the next dose level.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

  5. Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group

    The change from baseline in CD4 cell count was summarized for each visit during the treatment phase for each treatment group. The time-weighted mean of change of the post baseline (visit TE1) values was calculated. The time-weighted mean was adjusted AUC (area under the curve) by time.

    Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

07

Results

Posted Oct 30, 2025
Limitations and caveats
FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.

Participant flow

Participant flow — Overall Study
MilestonePRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Started81830
Completed021
Not completed81629
Withdrew: Study early termination81629

Outcome measures

PrimaryLong Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.

The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table). Treatment-Emergent Serious Adverse Events (TESAEs) are defined as serious adverse events with an onset on or after the first treatment.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Number · participants
Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.
participantsPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Participants with Grade 2, 3, or 4 AEs566
Participants with TESAEs352
PrimaryProportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.

Virological failure is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Number · proportion of participants
Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.
proportion of participantsPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.00.170.37
SecondaryTime to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group.

Virological failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group. The date of VF event is defined as the date of the second assessment of the two (2) consecutive HIV-1 RNA levels of \>= 200 copies/mL when virological failure is confirmed. Subjects who did not have VF, the last visit date will be used as the date of the event.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Mean · days
Time to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group.
daysPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Time to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group.1148.88 ± 457.15735.67 ± 326.71582.00 ± 407.71
SecondaryProportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.

Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Number · Portion of Participants
Proportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.
Portion of ParticipantsPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Proportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.—10.9
SecondaryTime to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.

Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Mean · days
Time to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.
daysPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Time to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.—100.33 ± 33.48136.71 ± 127.68
SecondaryProportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group.

Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group. Subjects who experienced virologic failure during the treatment phase had an option to re-initiate their PRO 140 regimen to their previous baseline or dose escalate to the next dose level.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Number · proportion of participants
Proportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group.
proportion of participantsPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Proportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group.—0.330.78
SecondaryMean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group

The change from baseline in CD4 cell count was summarized for each visit during the treatment phase for each treatment group. The time-weighted mean of change of the post baseline (visit TE1) values was calculated. The time-weighted mean was adjusted AUC (area under the curve) by time.

Time frame:
From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Reported as:
Mean · cells/uL
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group
cells/uLPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group0.62 ± 2.60-0.14 ± 2.590.58 ± 2.32

Adverse events

Collected over Report initiation for all adverse events began at the time of the first treatment extension visit and continued up until the final study visit (up to approximately 197 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRO 140 350 mg1/8 (12.5%)3/8 (37.5%)6/8 (75%)
PRO 140 525 mg1/18 (5.6%)5/18 (27.8%)9/18 (50%)
PRO 140 700 mg0/30 (0%)2/30 (6.7%)18/30 (60%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
Atrioventricular block completeCardiac disorders1/80/180/30
Lacunar infarctionNervous system disorders1/80/180/30
Lower limb fractureInjury, poisoning and procedural complications1/80/180/30
OverdoseInjury, poisoning and procedural complications1/80/180/30
Pancreatitis acuteGastrointestinal disorders0/82/180/30
COVID-19Infections and infestations0/81/180/30
COVID-19 pneumoniaInfections and infestations0/81/180/30
PancreatitisGastrointestinal disorders0/81/180/30
Pancreatitis necrotisingGastrointestinal disorders0/81/180/30
Sleep Apnoea SyndromeRespiratory, thoracic and mediastinal disorders0/81/180/30
Most frequent other events
Showing 10 of 118
Most frequent other events
EventPRO 140 350 mgPRO 140 525 mgPRO 140 700 mg
DiarrhoeaGastrointestinal disorders3/82/181/30
NasopharyngitisInfections and infestations3/83/181/30
Seasonal allergyImmune system disorders3/81/180/30
Actinic keratosisSkin and subcutaneous tissue disorders2/80/180/30
Back painMusculoskeletal and connective tissue disorders2/81/181/30
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/80/180/30
Dental cariesGastrointestinal disorders2/81/180/30
DysuriaRenal and urinary disorders2/80/180/30
FatigueGeneral disorders2/81/181/30
HypertensionVascular disorders2/80/180/30

Baseline characteristics

All patients who received at least one dose of PRO 140 (leronlimab) were included in the baseline analysis population. Study was early terminated.

Age, Categorical
Age, Categorical(Participants)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
<=18 years0000
Between 18 and 65 years7172852
>=65 years1124
Age, Continuous
Age, Continuous(years)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
Mean59.88 ± 8.3747.17 ± 11.9447.77 ± 13.1049.30 ± 12.90
Sex: Female, Male
Sex: Female, Male(Participants)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
Female1304
Male7153052
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
Hispanic or Latino0459
Not Hispanic or Latino8142547
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
American Indian or Alaska Native0101
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1247
White7132646
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)PRO 140 350 mgPRO 140 525 mgPRO 140 700 mgTotal
United States8183056
08

Study locations

1 site
  • Quest Clinical Research
    San Francisco, California 94115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jun 2022, 57 months.

Results were first posted in Oct 2025, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Mar 9, 2022
StartActual
Aug 29, 2017
Primary completionActual
Jun 20, 2022
CompletionActual
Jul 10, 2022
Results first posted
Oct 30, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05271370
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2022
Start date
Aug 29, 2017
Primary completion
Jun 20, 2022
Completion
Jul 10, 2022
Results posted
Oct 30, 2025
Last update
Oct 30, 2025

Study contacts

Jacob Lalezari, MD
principal investigator · CytoDyn, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion